Compounds and methods for the treatment of parasitic diseases

Patent metadata

Field	Value
Publication number	US-12414935-B2
Application number	US-202017604732-A
Country	US
Kind code	B2
Filing date	Apr 22, 2020
Priority date	Apr 23, 2019
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including cryptosporidiosis.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the structure of:

pharmaceutically acceptable salts thereof;

wherein said compound is present in a therapeutically effective amount to treat a disease caused by a parasite from the genus Cryptosporidium.

2. The pharmaceutical composition according to claim 1 , formulated as a veterinary composition.

3. The pharmaceutical composition according to claim 1 , wherein said disease is cryptosporidiosis.

4. A method of treatment or prophylaxis of a parasitic disease caused by a parasite from the genus Cryptosporidium comprising the step of administering to the subject an effective amount of a compound having the structure of:

pharmaceutically acceptable salts thereof.

5. The method of claim 4 , wherein said parasitic disease is cryptosporidiosis.

6. The method of claim 5 , wherein said cryptosporidiosis is carried by C. parvum.

7. The method of claim 4 , wherein said subject is human.

8. The method of claim 4 , wherein said subject is not human.

9. The method of claim 8 , wherein said subject is a mouse, rat, rabbit, non-human primate, lizard, gecko, cow, calf, sheep, lamb, horse, foal, pig, or piglet.

10. A method of treatment or prophylaxis of a parasitic disease caused from a parasite from the genus Cryptosporidium in a subject, comprising the step of administering to a subject the pharmaceutical composition of claim 1 .

11. The method of claim 10 , wherein said parasitic disease is cryptosporidiosis.

12. The method of claim 11 , wherein said cryptosporidiosis is carried by C. parvum.

13. The method of claim 10 , wherein said subject is human.

14. The method of claim 10 , wherein said subject is not human.

15. The method of claim 14 , wherein said subject is a mouse, rat, rabbit, non-human primate, lizard, gecko, cow, calf, sheep, lamb, horse, foal, pig, or piglet.

Assignees

• Washington University St Louis
• Broad Inst Inc
• Harvard College

Inventors

• Sibley Laurence David
• Melillo Bruno
• Comer Eamon

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• A61K31/397 Primary

  having four-membered rings, e.g. azetidine · CPC title